Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
SCUBE3 Antibody Therapy Rewires Cancer Signaling
2026-08-11
The reference study identifies secreted SCUBE3 as a multifunctional cancer dependency that links oncogenic receptor signaling, DNA damage repair, therapy resistance, and immune suppression. Its neutralizing antibody approach produced antitumor activity in preclinical models by disrupting SCUBE3-associated FOXR2 and c-Myc signaling while restoring immune-related gene expression.
-
Rimonabant (SR141716) in Mechanistic Pain Assays
2026-08-10
Rimonabant (SR141716) gives researchers a selective CB1 blockade tool for separating cannabinoid-dependent behavior from adenosine A2A-mediated effects in terpene and neuropathic-pain studies. Its high CB1 selectivity also supports appetite regulation research, obesity research, inflammatory assays, and controlled endocannabinoid-system experiments.
-
Phenacetin in Human Intestinal Organoid PK
2026-08-09
Phenacetin can serve as a chemically defined benchmark for translational pharmacokinetic studies when evaluated in human pluripotent stem cell-derived intestinal organoids. This article connects the compound’s absorption and metabolism questions with recent organoid advances, while emphasizing vehicle control, analytical endpoints, nephropathy-related safety boundaries, and research-only use.
-
Doxorubicin: From DNA Damage to Cardiotoxicity
2026-08-08
Doxorubicin, also known as Adriamycin, is a powerful DNA-directed cancer chemotherapy drug and a valuable mechanistic probe. This article connects its tumor-cell activity with cardiotoxicity research and shows how assay design, timing, and orthogonal readouts improve interpretation.
-
6-Thioguanine Chitosan Nanoparticles in Cancer Models
2026-08-07
This study investigated chitosan nanoparticles as a delivery system for 6-thioguanine, with or without curcumin, to address the drug’s limited bioavailability and short half-life. The formulation produced sustained release and stronger in vitro responses than free 6-thioguanine in selected breast and ovarian cancer models, while also providing evidence of apoptosis, G2/M arrest, and DNA demethylating activity.
-
Precision Caspase-3/7 Inhibition: Translational Impact for A
2026-08-07
Explore the mechanistic depth and translational strategies enabled by selective, reversible caspase-3/7 inhibition. This article integrates recent host-pathogen research, advanced workflow insights, and practical guidance for leveraging Caspase-3/7 Inhibitor I in apoptosis modulation—from mechanistic cell death dissection to disease model innovation.
-
GSH and GSSG Assay Kit: Redefining Reduced Glutathione Detec
2026-08-06
The GSH and GSSG Assay Kit delivers unmatched sensitivity and workflow flexibility for quantifying redox state dynamics in diverse biological samples. Its robust protocol, validated in advanced immunometabolism and tumor microenvironment research, empowers researchers to unravel oxidative stress mechanisms with confidence.
-
Nintedanib (BIBF 1120) Precision: Tumor Angiogenesis and ATR
2026-08-06
Explore how Nintedanib (BIBF 1120) targets angiogenesis and reveals new vulnerabilities in ATRX-deficient cancer cells. This article delivers deep mechanistic insights and practical guidance for antiangiogenic research, setting it apart from prior content.
-
Phosphotungstic Acid Negative Stain Solution: Advanced EM Wo
2026-08-05
Unlock precision virus and glycan visualization with 2% Phosphotungstic Acid Negative Stain Solution from APExBIO. This guide delivers step-by-step EM protocols, real-world troubleshooting, and cross-domain insights for antiviral research.
-
AMD-070 Hydrochloride: Empowering CXCR4 Antagonist Workflows
2026-08-05
Mavorixafor hydrochloride (AMD-070 hydrochloride) sets a new standard for targeting the CXCR4/CXCL12 axis, enabling robust, reproducible results in immunology and anti-HIV research. With exceptional solubility and selectivity, it transforms experimental reliability and clinical translation, especially in rare immunodeficiencies like WHIM syndrome.
-
p-Cresyl Sulfate Drives Aortic Valve Calcification via Kloth
2026-08-04
This study defines how p-Cresyl sulfate (PCS), a uremic toxin, accelerates calcification of aortic valvular interstitial cells (VICs) through modulation of klotho and sirtuin-1 (SIRT1) signaling. The findings reveal mechanistic links between PCS accumulation in chronic kidney disease and increased cardiovascular risk, highlighting actionable targets for future interventions.
-
Celastrol-Induced Mitophagy via CAV-1 Modulates Liver Cancer
2026-08-04
This study uncovers a novel mechanism by which celastrol triggers mitophagy in liver cancer through CAV-1-mediated mitochondrial cholesterol metabolism. The findings suggest that targeting organelle-specific cholesterol trafficking could represent a new therapeutic strategy in hepatocellular carcinoma.
-
KNSTRN Knockdown Disrupts Autophagic Flux in Bladder Cancer
2026-08-03
The referenced study unveils that KNSTRN knockdown impairs autophagic flux by inducing lysosomal dysfunction via ROS accumulation, suppressing bladder cancer cell viability and tumor progression. These mechanistic insights highlight KNSTRN as a potential therapeutic target and clarify the complex interplay between autophagy, mitosis, and cancer cell survival.
-
ERK5 and ERK1/2 Pathway Roles in Vitamin D3-Induced AML Diff
2026-08-03
This article examines a pivotal study revealing that the ERK5/MAPK pathway critically modulates terminal differentiation and cell cycle arrest in myeloid leukemia cells exposed to 1α,25-(OH)2 vitamin D3. The findings clarify mechanistic distinctions between ERK1/2 and ERK5 signaling, informing targeted cancer research strategies.
-
Pam3CSK4: Precision TLR1/2 Agonist for Advanced Inflammation
2026-08-02
Discover how Pam3CSK4 enables precise TLR1/2-driven immune cell activation and delivers actionable insights for dissecting neuro-immune interactions in inflammation research. This article unpacks the molecular mechanism, protocol nuances, and translational potential, providing a new depth beyond existing perspectives.